Patents by Inventor Bernd Buettelmann

Bernd Buettelmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7538132
    Abstract: The present invention is concerned with aryl-isoxazole-4-carbonyl-pyrrole-2-carboxylic acid amide derivatives of formula wherein R1, R2, R3, R4, and R5, and m are as defined herein and with their pharmaceutically acceptable acid addition salts. This class of compounds have high affinity and selectivity for GABA A ?5 receptor binding sites and therefore may be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: May 26, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Matthias Heinrich Nettekoven, Andrew William Thomas
  • Patent number: 7531529
    Abstract: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment of genitourinary diseases.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 12, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Bernd Buettelmann, Simona Maria Ceccarelli, Georg Jaeschke, Sabine Kolczewski, Richard Hugh Philip Porter, Eric Vieira, Anthony P. D. W. Ford, Yu Zhong
  • Patent number: 7507729
    Abstract: The present invention is concerned with substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein the definition of substituents is described in the claims. This class of compounds shows high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as a cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: March 24, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Henner Knust, Andrew Thomas
  • Publication number: 20090018171
    Abstract: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3, R4, X, Y and R are described hereinabove, or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the imidazole derivatives of formula I, a process for preparing a compound of formula I, and a method of treating or preventing acute and/or chronic neurological disorder comprising administering to a patient in need of such treatment and/or prevention a therapeutically effective amount of said pharmaceutical composition. These disorders include Alzheimer's disease. These disorders also include mild cognitive impairment.
    Type: Application
    Filed: September 17, 2008
    Publication date: January 15, 2009
    Inventors: Bernd Buettelmann, Simona Maria Ceccarelli, Georg Jaeschke, Sabine Kolczewski, Richard Hugh Philip Porter, Eric Vieira
  • Publication number: 20090005370
    Abstract: The present invention is concerned isoxazole-imidazole derivatives having affinity and selectivity for GABA A ?5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use for enhancing cognition or for the treatment of cognitive disorders like Alzheimer's disease. In particular, the present invention is concerned with aryl-isoxazol-4-yl-imidazole derivatives of formula I wherein R1, R2 and R3 are as described in the specification.
    Type: Application
    Filed: June 16, 2008
    Publication date: January 1, 2009
    Inventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Andrew Thomas
  • Publication number: 20080287458
    Abstract: Compounds of formula I are effective modulators of JNK: wherein X is CR11 or N; Y is —C(O)R3, 5-membered heteroaryl, or 5-membered heterocyclyl; Z is phenyl, cycloalkyl, heterocyclyl or heteroaryl, and is substituted with R1 and R2; R1 and R2 are each independently H, halo, CN, lower alkyl, or —Y1—Y2—Y3—R8, or R1 and R2 together form —O(CH2)nO—, where n is 1 or 2; Y1 is —O—, —C(O)—, —C(O)O—, —C(O)NR9—, —NR9C(O)—, —S—, —SO2—, or a bond; Y2 is cycloalkylene, heterocycloalkylene, lower alkylene or a bond; Y3 is —O—, —C(O)—, —C(O)O—, —C(O)NR9—, —NR9C(O)—, —SO2—, or a bond; R8 is H, lower alkyl, lower alkoxy, cycloalkyl, heterocycloalkyl, or —NR9R10, wherein R8 other than H is optionally substituted with lower alkyl, halo, —CF3, or —OH; R9 and R10 are each independently H or lower alkyl; R3 is OH, lower alkyl, lower alkoxy, (lower alkoxy)-lower alkoxy, or —NR9R10; R4 is lower alkyl, phenyl, heterocyclyl, cycloalkyl, heterocycloalkyl, or heteroaryl, and is optionally substituted with lower alkyl, hydroxy
    Type: Application
    Filed: May 14, 2008
    Publication date: November 20, 2008
    Inventors: Sarah C. Abbot, Genevieve N. Boice, Bernd Buettelmann, David Michael Goldstein, Leyi Gong, Joan Heather Hogg, Pravin Iyer, Kristen Lynn McCaleb, Yun-chou Tan
  • Patent number: 7452909
    Abstract: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3, R4, X, Y and R are described hereinabove, or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the imidazole derivatives of formula I, a process for preparing a compound of formula I, and a method of treating or preventing acute and/or chronic neurological disorder comprising administering to a patient in need of such treatment and/or prevention a therapeutically effective amount of said pharmaceutical composition. These disorders include Alzheimer's disease. These disorders also include mild cognitive impairment.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: November 18, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona Maria Ceccarelli, Georg Jaeschke, Sabine Kolczewski, Richard Hugh Philip Porter, Eric Vieira
  • Patent number: 7432256
    Abstract: The present invention is concerned with substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the formula I wherein R1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, nitro, cycloalkyl, —O(CH2)mO(CH2)mOH or —C?C—R?; R2 is hydrogen or methyl; R3 is lower alkyl, lower alkyl substituted by halogen, lower alkenyl, lower alkenyl substituted by halogen, lower alkynyl, —(CH2)n-cycloalkyl, —(CR?R?)m—CH3, phenyl that is unsubstituted or substituted by halogen, pyridinyl or thienyl each of which is unsubstituted or substituted by lower alkyl, —(CH2)n—NH-cycloalkyl, lower alkenyl-cycloalkyl, lower alkynyl-(CR?R?)mOH, or lower alkynyl-phenyl wherein the phenyl ring is unsubstituited or substituted by halogen, CF3, lower alkyl or lower alkoxy; R? is hydrogen or lower alkyl; R? is hydrogen, hydroxy or lower alkyl; n is 0, 1 or 2; m is 1, 2 or 3; and o is 1 or 2; and pharmaceutically acceptable acid addition salts th
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: October 7, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Henner Knust, Andrew William Thomas
  • Patent number: 7414061
    Abstract: The present invention is concerned with aryl-isoxazol-4-yl-imidazole derivatives of formula I: wherein R1 to R6 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: August 19, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andrew Thomas
  • Patent number: 7399769
    Abstract: The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives of formula wherein: R1, R2, and R3 are as defined herein and pharmaceutically acceptable acid addition salts thereof. These compounds have high affinity and selectivity for GABA A ?5 receptor binding sites. The invention also relates to methods for enhancing cognition and treating cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 15, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Jiaqiang Dong, Bo Han, Henner Knust, Andrew Thomas
  • Patent number: 7388025
    Abstract: The present invention is concerned with 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives of formula I wherein R1, R2, and R3 are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. These compounds have a high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: June 17, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Matthias Nettekoven, Andrew Thomas
  • Patent number: 7378435
    Abstract: The present invention is concerned with aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives of formula I wherein R1, R2, R3, R4, and R5 are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. The invention also relates to methods for preparing such compounds. This class of compounds has a high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease. Thus, the invention also is concerned with pharmaceutical compositions containing compounds of formula I or their pharmaceutically acceptable acid addition salts and methods for the treatment of GABA A?5 mediated diseases, including Alzheimer's disease.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: May 27, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Matthias Nettekoven, Andrew Thomas
  • Publication number: 20080119489
    Abstract: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognititve disorders and memory deficits, as well as chronic and acute pain.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 22, 2008
    Inventors: Bernd Buettelmann, Simona Maria Ceccarelli, George Jaeschke, Sabine Kolczewski, Richard Hugh Philip Porter, Eric Vieira
  • Publication number: 20080103306
    Abstract: The present invention relates to process for the preparation of an imidazole derivative of formula I, wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and memory deficits, as well as chronic and acute pain.
    Type: Application
    Filed: December 13, 2007
    Publication date: May 1, 2008
    Inventors: Bernd Buettelmann, Simona Ceccarelli, Georg Jaeschke, Sabine Kolczewski, Richard Porter, Eric Vieira
  • Patent number: 7332510
    Abstract: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3 and R4 are described hereinbelow. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and memory deficits, as well as chronic and acute pain.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: February 19, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Simona Maria Ceccarelli, Georg Jaeschke, Sabine Kolczewski, Richard Hugh Philip Porter, Eric Vieira
  • Publication number: 20070287739
    Abstract: The present invention is concerned with aryl-4-ethynyl-isoxazole derivatives of formula I wherein R1 to R5 are as described in the specification and pharmaceutically acceptable salt thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites, being useful as a cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Application
    Filed: May 24, 2007
    Publication date: December 13, 2007
    Inventors: Bernd Buettelmann, Henner Knust, Andrew Thomas
  • Publication number: 20070191421
    Abstract: The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives of formula wherein: R1, R2, and R3 are as defined herein and pharmaceutically acceptable acid addition salts thereof. These compounds have high affinity and selectivity for GABA A ?5 receptor binding sites. The invention also relates to methods for enhancing cognition and treating cognitive disorders like Alzheimer's disease.
    Type: Application
    Filed: December 18, 2006
    Publication date: August 16, 2007
    Inventors: Bernd Buettelmann, Jiaqiang Dong, Bo Han, Henner Knust, Andrew Thomas
  • Publication number: 20070179178
    Abstract: The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives of formula I: wherein R1 to R5 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Application
    Filed: January 16, 2007
    Publication date: August 2, 2007
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andrew Thomas
  • Publication number: 20070161654
    Abstract: The present invention is concerned with aryl-isoxazol-4-yl-imidazole derivatives of formula I: wherein R1 to R6 are as defmed in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Application
    Filed: December 18, 2006
    Publication date: July 12, 2007
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andrew Thomas
  • Publication number: 20070161686
    Abstract: The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein R1, R2, and R3, are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Application
    Filed: December 15, 2006
    Publication date: July 12, 2007
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andreas Koblet, Andrew Thomas